Navigation Links
Enox Biopharma, Inc. Grants TTA LTD License To Wound Care Applications

VANCOUVER, British Columbia, June 26, 2012 /PRNewswire/ -- Enox Biopharma, Inc. (VANCOUVER, BC.), a leader in the development of innovative solutions for infections associated with medical devices and TTA LTD (Tel Aviv, Israel) today announced an execution of an exclusive royalty bearing license agreement under which Enox Biopharma shall grant TTA LTD rights to patent application and knowhow for use in developing novel therapies for wound care applications.

Under this agreement, Enox Biopharma assigned a recently filed provisional patent to TTA that covers novel means of delivering nitric oxide directly to wounds. Nitric oxide is well known in its ability to both prevent infections and act as a vasodilator which increases blood flow. Both of these are beneficial during the wound healing process. Direct exposure of a wound to nitric oxide has promise to facilitate the closing of chronic wounds that would not otherwise heal. TTA will use Enox Biopharma's innovation to develop innovative wound healing treatments and technologies. 

"This agreement allows for concurrent focused development at Enox of our core competency and technology related to rendering medical devices antimicrobial and at TTA of wound care applications," said John Rewcastle, Enox's CEO. "Both these are significant endeavors that require company focus. I have the utmost confidence that TTA will be successful in their efforts which will, of course, be beneficial to Enox."

Racheli Vizman, TTA LTD's COO commented, "The wound care market is massive and expected to exceed twenty billion dollars by 2015. Unfortunately for patients today the market is also underserved. We believe the technology developed by Enox has very significant potential to revolutionize the wound care field. TTA will be working to take the technology through the development and regulatory process."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to, catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

About TTA, LTD.

TTA Ltd. is a privately held, Israel-based company focuses on developing innovative topical therapeutics products for wound healing. 

For more information, please contact:

John C. Rewcastle, Ph.D, CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone
888.224.7259 fax

TTA contact information:

Racheli  Vizman,COO
Tel: +972-52-5659922
Fax: +972-3-9233228

SOURCE Enox Biopharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
2. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
3. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
4. Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
5. NSF CAREER grants support ocean energy, microforming, computer planning
6. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
7. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
8. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
9. ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012
10. HistoRx Licenses Melanoma Assay from Yale University
11. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), ... MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing ... AMA members have embraced this type of racing and several new model aviation pilots ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies would ... named to Deloitte's 2015 Technology Fast 500 list of the fastest growing companies ... FDA-cleared, Class II medical device that speeds up orthodontic tooth movement by as ...
Breaking Biology Technology:
(Date:10/26/2015)... ALTO, Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern ... Alliance , today announced the launch of its latest ... first unified platform enabling organizations to use standards-based authentication ... The Nok Nok S3 Authentication Suite is ideal for ...
(Date:10/23/2015)... Research and Markets ( ) has announced the ... 2015-2019" report to their offering. ... recognition biometrics market to grow at a CAGR of ... --> The report, Global Voice Recognition Biometrics ... market analysis with inputs from industry experts. The report ...
(Date:10/22/2015)... Oct. 22, 2015  Aware, Inc. (NASDAQ: AWRE ), a ... for its third quarter ended September 30, 2015.  ... of 2015 was $4.0 million, a decrease of 33% compared to ... the third quarter of 2015 was $2.2 million, or $0.10 per ... share, in the same period a year ago.  ...
Breaking Biology News(10 mins):